Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.420 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Merck Spinoff Organon Just Reported Its First Quarter — Here's What You Need To Know
Organon crushed Wall Street's second-quarter expectations on Thursday and announced its first dividend, leading OGN stock to pop. 
Via Investor's Business Daily
Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend
From Organon & Co.
Via Business Wire
ObsEva Stock Surges On Potential $500M Ebopiprant Deal For Preterm Labor
Organon & Co (NYSE: OGN) will license the global development, manufacturing, and commercial rights to ObsEva SA's (NASDAQ: OBSV) ebopiprant (OBE022)... 
Via Benzinga
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
From Organon
Via Business Wire
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
Unusual Options Activity Insight: UP Fintech Holding
Organon (NYSE:OGN) shares experienced unusual options activi... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS... 
Via Benzinga
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:... 
Via Benzinga
Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
From Organon & Co.
Via Business Wire
Why Ocugen Shares Are Rallying Today
Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling... 
Via Benzinga
3 Stocks I'd Avoid at All Costs
On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away. 
Via The Motley Fool
Stay Away From Low-Growth Organon
Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive. 
Via InvestorPlace
Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
From Organon & Co.
Via Business Wire
Summer Friday
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets
Don’t Miss the Opportunity Presented by Organon Stock
If a company's spun off from a pharmaceutical giant, you'd think the buzz about it would be deafening. Yet OGN stock remains an underappreciated gem. 
Via InvestorPlace
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Organon Announces Filing of Form 10-Q for the Quarter Ended March 31, 2021
From Organon & Co.
Via Business Wire
Motivation Really Matters When It Comes to Organon
Though spun-off entities can perform very well, with OGN stock, you should assess which company is getting the better deal. 
Via InvestorPlace
Organon Completes Acquisition of Alydia Health – A Medical Device Company Focused on Postpartum Hemorrhage
From Organon & Co.
Via Business Wire
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021
Upgrades According to Argus Research, the prior rating for Zoom Video Communications Inc (NASDAQ:ZM) was changed from Hold to Buy. Zoom Video Communications earned $1.32... 
Via Benzinga
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.